Vaccines Articles
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
Regen BioPharma has filed a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented mRNA cancer immunotherapeutic vaccine.
The World Health Organization has prequalified the first malaria vaccine, RTS,S/AS01 (also known as Mosquirix), manufactured by GSK, bringing it closer to reaching millions more children at risk of malaria.
A study by researchers at Georgia State University's Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
U.S. researchers have developed a new mRNA vaccine against cancer that delivers the drug directly to the lymphatic system and simulates a strong immune response.
Results of a recent study shows Pfizer's experimental vaccine for respiratory syncytial virus is nearly 86 percent effective in preventing severe illness in older adults.
An experimental vaccine shows promise for protecting mice from the respiratory syncytial virus, the pathogen that most commonly causes the chest infection bronchiolitis in young children.
The U.S. Department of Health and Human Services will provide approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS, a vaccine approved to prevent smallpox and monkeypox.
NIAID has launched an early-stage clinical trial to evaluate an investigational preventive vaccine for Epstein-Barr virus (EBV).
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
New data from a Phase II clinical trial of Valneva SE and Pfizer Inc.’s Lyme disease vaccine candidate, VLA15, shows it produced strong immune responses, prompting preparations for a Phase III study in the third quarter of 2022.
NIAID has launched a Phase I clinical trial evaluating three experimental HIV vaccines based on a mRNA platform — a technology used in several approved COVID-19 vaccines.
